CureVac (CVAC) Gets a Buy Rating from JMP Securities

In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on CureVac (CVACResearch Report), with a price target of $52.00. The company’s shares closed last Thursday at $18.64, close to its 52-week low of $16.34.

According to, Buchanan is ranked 0 out of 5 stars with an average return of -13.4% and a 32.7% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Arbutus Biopharma, and Hookipa Pharma.

Currently, the analyst consensus on CureVac is a Hold with an average price target of $36.00, representing a 90.5% upside. In a report issued on January 28, Berenberg Bank also maintained a Buy rating on the stock with a $52.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $130.48 and a one-year low of $16.34. Currently, CureVac has an average volume of 739.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CureVac BV a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company’s product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.

Read More on CVAC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More